November 13, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full ...

Gilead Sciences, Inc. today announced the presentation of new research data from its innovative HIV treatment portfolio and pipeline, including a broad range of data on investigational and marketed ...

He expressed optimism that this growth will continue, driven by the potential approval of lenacapavir as a preventive ...

What is patent evergreening and what does the Indian patent regime tell us about it? Also, go beyond the nugget to know about ...

The results from the PURPOSE 2 study, which build on the 100% efficacy shown in PURPOSE 1, demonstrate lenacapavir's unmatched clinical profile observed for HIV prevention. If approved, lenacapavir, ...

Major purchases of the most advanced medical equipment and consumables, and cooperation on major infectious diseases such as ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on GILD stock, giving a Buy rating yesterday. Daina ...

We need nothing less than disruptive action to ensure everyone who wants access to affordable lenacapavir can get it.

Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...

Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...